Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

[1]  M. Triassi,et al.  COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak , 2020, Multiple Sclerosis and Related Disorders.

[2]  K. Schmierer,et al.  The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic , 2020, Multiple Sclerosis and Related Disorders.

[3]  G. Borriello,et al.  COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach , 2020, Multiple Sclerosis and Related Disorders.

[4]  G. Cutter,et al.  Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program , 2019, Revue Neurologique.

[5]  F. Fernandez‐Llimos,et al.  Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis , 2018, CNS Drugs.

[6]  G. Cutter,et al.  071 Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch® prescribing program , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[8]  R. Marrie,et al.  Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants , 2017, Neurology. Clinical practice.

[9]  B. Uitdehaag,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations , 2017, Multiple sclerosis.

[10]  M. Wattjes,et al.  The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing , 2017, Multiple sclerosis.

[11]  A. Schene,et al.  Childhood trauma and negative memory bias as shared risk factors for psychopathology and comorbidity in a naturalistic psychiatric patient sample , 2017, Brain and behavior.

[12]  H. Hartung,et al.  Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations , 2017, Multiple sclerosis.

[13]  C. Oreja-Guevara,et al.  Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation , 2017, Brain and behavior.

[14]  M. Clanet,et al.  Risk of relapse after natalizumab withdrawal , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[15]  H. Reichmann,et al.  New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies , 2016, Journal of Neuroinflammation.

[16]  Shin C. Beh,et al.  Extended interval dosing of natalizumab in multiple sclerosis , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[17]  R. Wilson.  MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study , 2015, Neurology.

[18]  M. Sormani,et al.  Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). , 2014, JAMA neurology.

[19]  R. Bomprezzi,et al.  Extended interval dosing of natalizumab: a two-center, 7-year experience , 2014, Therapeutic advances in neurological disorders.

[20]  X. Montalban,et al.  MS disease activity in RESTORE , 2014, Neurology.

[21]  P. Sørensen,et al.  Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients , 2014, Journal of Neurology.

[22]  E. Trinka,et al.  Natalizumab saturation: Biomarker for individual treatment holiday after natalizumab withdrawal? , 2013, Journal of the Neurological Sciences.

[23]  C. Polman,et al.  Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped , 2012, Multiple sclerosis.

[24]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[25]  S. Golaszewski,et al.  Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab—A Flow Cytometric Study on Patients with Multiple Sclerosis , 2012, PloS one.

[26]  X. Montalban,et al.  Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab , 2012, Multiple sclerosis.

[27]  E. Major,et al.  Immune reconstitution inflammatory syndrome in natalizumab-associated PML , 2011, Neurology.

[28]  L. Kappos,et al.  Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis , 2011, Neurology.

[29]  D. Centonze,et al.  Considerations on discontinuing natalizumab for the treatment of multiple sclerosis , 2010, Annals of neurology.

[30]  H. Urbach.  Comment to: Progressive Multifocal Leukoencephalopathy and Other Disorders Caused by JC Virus: Clinical Features and Pathogenesis , 2010, Clinical Neuroradiology.

[31]  I. Koralnik,et al.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis , 2010, The Lancet Neurology.

[32]  R. Ransohoff,et al.  Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.

[33]  Ludwig Kappos,et al.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring , 2007, The Lancet Neurology.

[34]  J. Bennett,et al.  Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. , 2007, CNS drug reviews.

[35]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[36]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[37]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[38]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[39]  R. Rudick,et al.  Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS , 2004 .

[40]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.